Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Insurance, Assurance and Insolence.

Texas medical journal (Austin, Tex.)·2023
Same author

Cross-tissue immune cell analysis reveals tissue-specific features in humans.

Science (New York, N.Y.)·2022
Same author

A method to isolate and cryopreserve cerebrospinal fluid mononuclear cells from external ventricular drains to investigate immunological processes in acute brain injuries.

Journal of immunological methods·2021
Same author

Risk factors for <i>Toxoplasma gondii</i> seropositivity in the Old Order Amish.

Epidemiology and infection·2020
Same author

Identification of a Sacral, Visceral Sensory Transcriptome in Embryonic and Adult Mice.

eNeuro·2020
Same author

The immunological response to traumatic brain injury.

Journal of neuroimmunology·2019

Related Experiment Video

Updated: Jul 26, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

Predictive markers in breast cancer--the present.

S J L Payne1, R L Bowen, J L Jones

  • 1Tumour Biology Laboratory, Institute of Cancer, John Vane Science Centre, Queen Mary's School of Medicine and Dentistry, London, UK.

Histopathology
|January 4, 2008
PubMed
Summary

This review covers established breast cancer markers: oestrogen receptor (ER), progesterone receptor (PR), and HER-2. It discusses their roles in prognosis, treatment response, and current assessment standards, highlighting limitations and future directions.

More Related Videos

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

Related Experiment Videos

Last Updated: Jul 26, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

Area of Science:

  • Oncology
  • Biomarker Research
  • Clinical Pathology

Background:

  • Breast cancer is a complex disease requiring accurate prognostic and predictive markers.
  • Established markers like oestrogen receptor (ER), progesterone receptor (PR), and HER-2 are crucial for patient management.
  • Current limitations exist in marker predictive power and assessment standardization.

Purpose of the Study:

  • To review the established roles of ER, PR, and HER-2 in breast cancer patient management.
  • To outline current standards for assessing these key biological markers.
  • To highlight existing controversies and potential refinements in marker assessment and utilization.

Main Methods:

  • Literature review of established breast cancer prognostic and predictive markers.
  • Analysis of current clinical guidelines and assessment standards for ER, PR, and HER-2.
  • Discussion of controversies and future directions in biomarker research for breast cancer.

Main Results:

  • Oestrogen receptor (ER) is a primary predictive marker for prognosis and hormone therapy response.
  • Progesterone receptor (PR) is widely used, though its predictive value is less defined than ER.
  • HER-2 status is a routine prognostic and predictive factor in breast cancer management.

Conclusions:

  • Robust and standardized assays for ER, PR, and HER-2 are essential for reliable patient management.
  • Understanding the limitations of current markers is key to refining breast cancer prognosis and treatment selection.
  • Further research into additional biological markers may enhance predictive accuracy.